NATALEE Trial Recruitment Criteria
The NATALEE trial enrolled adults (≥18 years) with HR+/HER2- early breast cancer who had anatomic stage IIA, IIB, or III disease, with specific high-risk features that varied by nodal status. 12
Key Eligibility Criteria
Patient Demographics
- Age: ≥18 years (women and men)
- Menopausal status: Any (premenopausal, postmenopausal, or men)
- Hormone receptor status: HR-positive/HER2-negative confirmed 13
Disease Stage Requirements
The trial included patients with anatomic stage II or III disease per AJCC 8th edition, specifically:
Stage IIA patients required:
- N1 disease (1-3 positive lymph nodes), OR
- N0 disease (node-negative) PLUS additional high-risk features:
Stage IIB or III patients:
Treatment Timing
- Initial diagnosis ≤18 months prior to randomization
- If already receiving standard (neo)adjuvant endocrine therapy, must have been initiated ≤12 months before randomization 1
Critical Distinctions from monarchE
NATALEE included a substantially broader population than monarchE, most notably by including select node-negative (N0) patients with high-risk features. 5 Real-world analysis showed 30.6% of HR+/HER2- EBC patients met NATALEE criteria versus only 14.5% for monarchE. 5
Among N0 patients (who comprised 74.9% of the real-world population), 9.5% were eligible for NATALEE while none qualified for monarchE. 5 Among N1 patients, 91.8% were NATALEE-eligible compared to 45.9% for monarchE. 5
FDA Approval Context
The FDA approved ribociclib based on NATALEE for adults with HR+/HER2- stage II and III EBC at high risk of recurrence, using the trial's inclusion criteria as the framework for identifying appropriate patients. 4 However, current ASCO guidelines note that adjuvant CDK4/6 inhibitor therapy may not provide meaningful clinical benefit to all trial-eligible patients, particularly lower-risk patients included in NATALEE, such as most node-negative cases. 6